Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
or

Cassava Sciences Inc (SAVA)

Cassava Sciences Inc (SAVA)
1.4500 -0.0100 (-0.68%) 11:48 ET [NASDAQ]
1.4400 x 800 1.4600 x 140
Realtime by (Cboe BZX)
1.4400 x 800 1.4600 x 140
Realtime 1.4793 +0.0193 (+1.32%) 09:28 ET
Quote Overview for Tue, Apr 22nd, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
1.4200
Day High
1.5000
Open 1.4300
Previous Close 1.4600 1.4600
Volume 282,476 282,476
Avg Vol 2,114,735 2,114,735
Stochastic %K 72.43% 72.43%
Weighted Alpha -70.20 -70.20
5-Day Change +0.1000 (+7.46%) +0.1000 (+7.46%)
52-Week Range 1.1500 - 42.2000 1.1500 - 42.2000
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 70,530
  • Shares Outstanding, K 48,308
  • Annual Sales, $ 0 K
  • Annual Income, $ -24,340 K
  • EBIT $ -141 M
  • EBITDA $ -140 M
  • 60-Month Beta -1.48
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.48

Options Overview Details

View History
  • Implied Volatility 105.67% ( +10.77%)
  • Historical Volatility 131.93%
  • IV Percentile 40%
  • IV Rank 5.48%
  • IV High 753.77% on 04/09/25
  • IV Low 68.09% on 01/16/25
  • Put/Call Vol Ratio 0.02
  • Today's Volume 155
  • Volume Avg (30-Day) 2,718
  • Put/Call OI Ratio 0.14
  • Today's Open Interest 90,099
  • Open Int (30-Day) 106,223

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Sell
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -1.41
  • Growth Rate Est. (year over year) +70,951.06%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1500 +25.22%
on 04/10/25
Period Open: 2.8400
2.9100 -50.52%
on 03/24/25
-1.4000 (-49.30%)
since 03/21/25
3-Month
1.1500 +25.22%
on 04/10/25
Period Open: 2.5900
3.0500 -52.79%
on 03/18/25
-1.1500 (-44.40%)
since 01/22/25
52-Week
1.1500 +25.22%
on 04/10/25
Period Open: 20.5000
42.2000 -96.59%
on 08/05/24
-19.0600 (-92.98%)
since 04/22/24

Most Recent Stories

More News
Cassava Announces Retirement of Chief Medical Officer, Dr. Jim Kupiec, and Appointment of Dr. Jack Moore as Senior Vice President, Clinical Development

SAVA : 1.4500 (-0.68%)
Cassava Sciences Stock Drops Over 30% After Alzheimer’s Drug Fails Study – But Retail Remains Hopeful

The drug showed no treatment benefit for patients in the study called REFOCUS-ALZ, the company said, while adding that the Alzheimer’s disease development program with Simufilam will be discontinued...

VTI : 257.71 (+2.02%)
IWM : 186.09 (+1.83%)
SAVA : 1.4500 (-0.68%)
Cassava Sciences Reports Topline Phase 3 REFOCUS-ALZ Data

SAVA : 1.4500 (-0.68%)
Cassava Sciences Reports 2024 Financial Results and Provides Business Update

SAVA : 1.4500 (-0.68%)
Cassava Sciences Licenses Simufilam Method of Treatment Patent

SAVA : 1.4500 (-0.68%)
Cassava Sciences Provides a Business Update

SAVA : 1.4500 (-0.68%)
Contact Levi & Korsinsky by February 10, 2025 Deadline to Join Class Action Against Cassava Sciences, Inc. (SAVA)

New York, New York--(Newsfile Corp. - January 2, 2025) - Levi & Korsinsky, LLP notifies investors in Cassava Sciences, Inc. ("Cassava Sciences, Inc." or the "Company") (NASDAQ: SAVA) of a class action...

SAVA : 1.4500 (-0.68%)
Anavex Sciences Soars On Earnings Relief, EU Filing Acceptance For Alzheimer’s Drug: Retail’s Overjoyed

The broader market’s interest in Alzheimer’s therapies remains intense, particularly after Cassava Sciences reported disappointing results for its candidate simufilam last month.

AVXL : 8.99 (+2.63%)
SAVA : 1.4500 (-0.68%)
News Movers: Your Daily Digest of Stocks That Released News Which Moved the Market

SURG : 2.69 (+0.19%)
PSTX : 9.50 (-0.63%)
KULR : 1.1850 (+4.87%)
TOYO : 2.84 (+0.18%)
AVXL : 8.99 (+2.63%)
MAXN : 2.66 (+5.14%)
POET : 3.82 (+2.69%)
SAVA : 1.4500 (-0.68%)
News Movers: Your Daily Digest of Stocks That Released News Which Moved the Market

WealthyVC.com scans North America’s 10,000+ publicly listed stocks across all seven exchanges to find the market-moving news that matters. Our focus is on quality, liquid, growth-oriented companies in...

SURG : 2.69 (+0.19%)
KULR : 1.1850 (+4.87%)
PSTX : 9.50 (-0.63%)
AVXL : 8.99 (+2.63%)
TOYO : 2.84 (+0.18%)
MAXN : 2.66 (+5.14%)
PTK.VN : 5.290 (+2.92%)
POET : 3.82 (+2.69%)
SAVA : 1.4500 (-0.68%)

Business Summary

Cassava Sciences Inc. is focused on the early detection and treatment of neurodegenerative diseases, such as Alzheimer's. Cassava Sciences Inc., formerly known as Pain Therapeutics Inc., is based in Austin, United States.

See More

Key Turning Points

3rd Resistance Point 1.6300
2nd Resistance Point 1.5600
1st Resistance Point 1.5100
Last Price 1.4500
1st Support Level 1.3900
2nd Support Level 1.3200
3rd Support Level 1.2700

See More

52-Week High 42.2000
Fibonacci 61.8% 26.5189
Fibonacci 50% 21.6750
Fibonacci 38.2% 16.8311
Last Price 1.4500
52-Week Low 1.1500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro